Bioresorbable Scaffold vs. Second Generation Drug Eluting Stent in Long Coronary Lesions requiring Overlap: A Propensity-Matched Comparison (the UNDERDOGS study).

[1]  R. Ferrari,et al.  Bioresorbable vascular scaffold overlap evaluation with optical coherence tomography after implantation with or without enhanced stent visualization system (WOLFIE study): a two-centre prospective comparison , 2016, The International Journal of Cardiovascular Imaging.

[2]  Yangsoo Jang,et al.  Effect of Intravascular Ultrasound-Guided vs Angiography-Guided Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. , 2015, JAMA.

[3]  A. Colombo,et al.  Impact of Strut Width in Periprocedural Myocardial Infarction: A Propensity-Matched Comparison Between Bioresorbable Scaffolds and the First-Generation Sirolimus-Eluting Stent. , 2015, JACC. Cardiovascular interventions.

[4]  S. Achenbach,et al.  Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  A. Colombo,et al.  Procedural feasibility and clinical outcomes in propensity-matched patients treated with bioresorbable scaffolds vs new-generation drug-eluting stents. , 2015, The Canadian journal of cardiology.

[6]  C. Di Mario,et al.  Optical coherence tomography evaluation of overlapping everolimus-eluting bioresorbable vascular scaffold implantation guided by enhanced stent visualization system. , 2015, International journal of cardiology.

[7]  Antonio Colombo,et al.  Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[8]  J. Tijssen,et al.  Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[9]  P. Serruys,et al.  A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial , 2015, The Lancet.

[10]  P. Serruys,et al.  Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary ste , 2015, JACC. Cardiovascular interventions.

[11]  R. Ferrari,et al.  Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. , 2014, International journal of cardiology.

[12]  T. Münzel,et al.  Immediate, acute, and subacute thrombosis due to incomplete expansion of bioresorbable scaffolds. , 2014, JACC. Cardiovascular interventions.

[13]  Helmut Baumgartner,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[14]  C. Di Mario,et al.  ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. , 2014, JACC. Cardiovascular interventions.

[15]  G. Stone,et al.  Coronary artery calcification: pathogenesis and prognostic implications. , 2014, Journal of the American College of Cardiology.

[16]  M. Mack,et al.  Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). , 2013, Journal of the American College of Cardiology.

[17]  R. Ferrari,et al.  Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction. , 2013, International journal of cardiology.

[18]  R. Virmani,et al.  Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice. , 2013, JACC. Cardiovascular interventions.

[19]  M. Valgimigli,et al.  Effects of pre‐hospital clopidogrel administration on early and late residual platelet reactivity in ST‐segment elevation myocardial infarction patients undergoing primary intervention , 2013, Journal of thrombosis and haemostasis : JTH.

[20]  F. Gaita,et al.  Use and misuse of multivariable approaches in interventional cardiology studies on drug-eluting stents: a systematic review. , 2012, Journal of interventional cardiology.

[21]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[22]  P. Serruys,et al.  Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: Insights from the ABSORB and SPIRIT trials , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[23]  Patrick W Serruys,et al.  From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? , 2012, European heart journal.

[24]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.

[25]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.